Last updated on August 2019

A Phase 3 Open-Label Study of ALXN1210 in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria (PNH)


Brief description of study

The purpose of this study is to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety, and efficacy of ALXN1210 in pediatric patients with paroxysmal nocturnal hemoglobinuria (PNH).

Clinical Study Identifier: NCT03406507

Find a site near you

Start Over

Clinical Trial Site

Atlanta, GA United States
  Connect »

Clinical Trial Site

Milwaukee, WI United States
  Connect »

Clinical Trial Site

Utrecht, Netherlands
  Connect »

Clinical Trial Site

Leeds, United Kingdom
  Connect »

Clinical Trial Site

London, United Kingdom
  Connect »

Clinical Trial Site

Saint Petersburg, Russian Federation
  Connect »